Program 2: Experimental Therapeutics

HCCC实验治疗(ET)计划的首要目标是开发和测试新的 癌症治疗学。为了实现这一目标，ET有三个中心研究主题：1)治疗目标和 先导发现，2)新的药物给药方法，3)临床治疗。ET有30个正式成员和 17个准会员。会员预约了3所学院(医学、药学和文科 和科学)和11个系。许多ET成员对不止一个主题做出了贡献。总对等- 经审查的ET年度研究经费为433万美元(NCI为2.44美元)，其中1044万美元用于 非同行评审的研究项目。ET成员具有很高的生产力和协作性。ET成员已经 自2011年4月1日以来撰写或合著了305篇癌症相关出版物，其中49%(n=148)涉及 治疗目标和线索发现，14%(n=43)涉及新的药物输送方法，36% (n=108)涉及临床治疗学。19%(n=59)是程序内，37%(n=113)是程序间 方案，30%(n=93)机构间。26篇稿件发表在影响力较大的期刊上 (影响系数&>10)。在治疗目标和线索发现主题中，研究人员小组合作 基于针对特定途径以及癌症类型的实验疗法。在小说中 给药途径主题，ET研究人员正在评估纳米粒、适配子和新型药物 治疗前列腺癌、淋巴瘤、黑色素瘤和乳腺癌的癌症免疫治疗方法。 临床治疗学主题的研究人员正在探索临床治疗学和 参与或领导145项活跃的临床试验，涉及多种癌症类型，通过 疾病特异性多学科肿瘤学小组(MOGS)。作为一个项目，ET的一个日益关注的焦点是 通过发育促进有前景的分子靶向治疗方法的进展 治疗流水线。

The overarching goal of the HCCC Experimental Therapeutics (ET) program is to develop and test novel cancer therapeutics. To accomplish this, ET has three central research themes: 1) Therapeutic Targets and Lead Discovery, 2) Novel Drug Delivery Approaches and 3) Clinical Therapeutics. ET has 30 full members and 17 associate members. Members have appointments across 3 colleges (Medicine, Pharmacy and Liberal Arts and Sciences) and 11 departments. Many ET members contribute to more than one theme. Total peer- reviewed annual research funding to ET is $4.33 million ($2.44 from the NCI) with $10.44 million in funding for non-peer reviewed research projects. ET members are highly productive and collaborative. ET members have authored or co-authored 305 cancer-related publications since April 1, 2011 with 49% (n=148) addressing therapeutic targets and lead discovery, 14% (n=43) addressing novel drug delivery approaches and 36% (n=108) addressing clinical therapeutics. 19% (n=59) were intra-programmatic, 37% (n=113) inter- programmatic, and 30% (n=93) inter-institutional. 26 manuscripts were published in high impact journals (impact factor >10). In the Therapeutic Targets and Lead Discovery theme, groups of investigators collaborate based on experimental therapeutics geared towards specific pathways, as well as cancer types. In the Novel Drug Delivery Approaches theme, ET investigators are evaluating nanoparticles, aptamers and novel approaches to cancer immunotherapy for treating prostate cancer, lymphoma, melanoma and breast cancer. Investigators in the Clinical Therapeutics theme are exploring mechanisms of action of clinical therapeutics and participating in or leading 145 active clinical trials across a spectrum of cancer types as coordinated through the disease specific Multidisciplinary Oncology Groups (MOGs). As a program, an increasing focus of ET is to facilitate movement of promising molecularly-targeted therapeutic approaches through the developmental therapeutics pipeline.